AcrB-IN-6
AcrB-IN-6 is an effective AcrB inhibitor. AcrB-IN-6 The compound inhibits the function of bacterial multidrug efflux pumps, thereby significantly enhancing the antibacterial activity of various antibiotics. AcrB-IN-6 achieves 32-fold MIC reductions in wild-type E. coli BW25113. AcrB-IN-6 exhibits excellent synergistic antibacterial effects, low cytotoxicity and hemolytic properties. AcrB-IN-6 can be used for researching anti-resistant bacteria.
For research use only. We do not sell to patients.
- CAS No.: 3082621-32-4
- Formula: C28H33BrN2O2
- Molecular Weight:509.48
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
AcrB-IN-6 (Compound 11i) (1-512 μg/mL) does not show any antibacterial activity against wild-type E. coli<.i> BW25113 or the BW25113 ΔAcrB mutant but demonstrates synergistic activity with six distinct antibiotics included Linezolid (HY-10394), Oxacillin (HY-B0925A), Azithromycin (HY-17506), Erythromycin (HY-B0220), Tetracycline (HY-A0107), Fusidic acid (HY-B1350), Minocycline (HY-17412A), Ampicillin (HY-B0522) and Piperacillin (HY-B1923)[1].
AcrB-IN-6 (50 μM, 0-5 min) inhibits Nile Red activity in wild-type E. coli BW25113[1].
AcrB-IN-6 (128 μg/mL, 0-20 min) does not disrupt the outer membrane permeability and and inner membrane proton motive force of the wild-type E. coli BW25113[1].
AcrB-IN-6 (2-256 μg/mL) does not cause hemolysis of mouse red blood cells and is low cytotoxicity toward mammalian cells[1].
Mcl-1-IN-16 (128 μg/mL, 0-12 h) enhances the post-antibiotic effect of Azithromycin in E. coli BW25113[1].
Mcl-1-IN-16 (16-128 μg/mL, 24 h) combined with Azithromycin and Linezolid exhibits significantly inhibitory effect on biofilm[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Parmacokinetics
| Species | Dose | Route | T1/2 | Cmax | Tmax | AUC0-t | AUC0-∞ | CL | MRT0-t | MRT0-∞ | F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mice[1] | 0.5 mg/kg | i.v. | 10.45 h | 361.26 ng/mL | 0.25 h | 1623 ng·h/mL | 4824.16 ng·h/mL | 207.24 mL/h/kg | 2.73 h | 14.90 h | / |
| Mice[1] | 1 mg/kg | i.v. | 12.73 h | 358.20 ng/mL | 0.25 h | 1612.74 ng·h/mL | 5679.26 ng·h/mL | 177.55 mL/h/kg | 2.75 h | 18.23 h | / |
| Mice[1] | 1.5 mg/kg | i.v. | 12.54 h | 360.20 ng/mL | 0.25 h | 1634.08 ng·h/mL | 5689.69 ng·h/mL | 175.92 mL/h/kg | 2.75 h | 17.96 h | / |
| Mice[1] | 2.5 mg/kg | i.p. | 9.89 h | 944.68 ng/mL | 0.50 h | 2866.06 ng·h/mL | 8292.25 ng·h/mL | 608.42 mL/h/kg | 2.74 h | 14.20 h | / |
| Mice[1] | 5 mg/kg | i.p. | 9.12 h | 964.90 ng/mL | 0.50 h | 2947.62 ng·h/mL | 8074.07 ng·h/mL | 627.47 mL/h/kg | 2.72 h | 15.47 h | 35.54 % |
| Mice[1] | 7.5 mg/kg | i.p. | 10.75 h | 918.02 ng/mL | 0.50 h | 2841.59 ng·h/mL | 8826.55 ng·h/mL | 570.45 mL/h/kg | 2.74 h | 13.13 h | / |
In Vivo
AcrB-IN-6 (5-10 mg/kg, i.p., applied to the wound, for 8 days) enhances the efficacy of Azithromycin in eliminating bacteria during skin infections in mice[1].
AcrB-IN-6 (250-1000 mg/kg, injected in the hemocoel, single dose) demonstrated good safety even at extremely high doses in the Galleria mellonella larvae[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:E. coli BW25113 infection model established in male SPF Kunming (KM) mice (20-22 g)[1]
-
Dosage:25 mg/kg (monotherapy); 5 and 15 mg/kg with Tetracycline
-
Administration:Intraperitoneal injection (i.p.), single dose
-
Result:Decreased CFU by approximately 0.5 log10 alone. Proved a more remarkable effect with Tetracycline.
-
Animal Model:Skin would bacterial infection model established in male SPF Kunming (KM) mice (20-22 g)[1]
-
Dosage:5 and 10 mg/kg with Azithromycin
-
Administration:Applied to the wound, once daily for 8 days
-
Result:Significantly reduced the bacterial load in the heart, liver, spleen, lungs and kidneys, and completely eliminate the bacteria in some organs.
Showed the same epidermal layer thickness and keratinization condition as normal skin, with no significant pathological changes.
Reduced the level of IL-6.
Chemical Information
-
CAS No. 3082621-32-4
-
Molecular Weight 509.48
-
Formula C28H33BrN2O2
-
SMILES
O=C(N1CCCCC1)CN2C3=C(C4=C2C=C(OCC5=CC=C(Br)C=C5)C=C4)CC(C)(C)CC3
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Bacterial live/dead nucleic-acid viability staining
The LIVE/DEAD bacterial viability staining method is based on differential permeability of nucleic-acid-binding fluorescent dyes, most commonly SYTO 9 and propidium iodide (PI), which enables discrimination of bacterial populations with intact versus compromised cytoplasmic membranes. SYTO 9 penetrates both intact and damaged bacterial membranes and binds nucleic acids to produce green fluorescence, whereas propidium iodide penetrates only cells with compromised membranes and fluoresces red while also reducing SYTO 9 signal through competitive binding and fluorescence interactions. The resulting fluorescence pattern is interpreted as a proxy for membrane integrity, which is widely used as an indicator of bacterial viability in microscopy, flow cytometry, and spectroscopic platforms. However, mechanistic studies show that SYTO 9 and PI interactions involve displacement and fluorescence resonance energy transfer effects, which can influence signal interpretation depending on dye ratios a
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)